drugset
drugset / Trial / NCT05718375

Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

NCT05718375 ↗

Phase 2 Completed 240 enrolled Curacle Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.

Timeline

Start
2023-02-14
Primary completion
2025-11-12
Completion
2025-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CU01-1001 Unknown 120 mg Oral

Indications

diabetic kidney disease